The content on this site is intended for healthcare professionals only
Dr Guillermo Villacampa speaks to ecancer about a study he presented at the ESMO Breast 2024 meeting on an an individual-patient level meta-analysis of patients with HER2-positive breast cancer which evaluated the association between HER2DX assay and survival outcomes.
He explains that his team combined cohorts such as randomised clinical trials, single-arm studies and observational studies in the adjuvant and neo-adjuvant setting with a primary endpoint of event-free survival.
Dr Villacampa reports that out of the 2031 patients the 6-years EFS was 93% for those identified as HER2DX low-risk and 82.9% for those at HER2DX high-risk.
Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC
ASCO 2024: Lung cancer highlights
Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy
ASCO 2024: Lung cancer roundup
Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients
OncoAlert round up July 28th to August 3rd, 2023
Nine-weeks trastuzumab still effective compared with one year trastuzumab for early-stage HER2 positive breast cancer
Breast cancer in elderly patients: a clinicopathological review of a Nigerian database
Addition of platinum to standard neoadjuvant chemotherapy improves EFS in patients with TNMBC
